



Cerebral Slow Flow: An Emerging Phenomenon in Vascular Dementia Pathogenesis

Uğur Özkan, Fatih Kardeş, Umutcan Vurucu, Kenan Yalta

Department of Cardiology, Trakya University Faculty of Medicine, Edirne, Türkiye

Dementia poses a major global health burden, currently affecting more than 55 million individuals worldwide, with vascular dementia ranking as the second most prevalent form after Alzheimer's disease. The pathogenesis of vascular cognitive impairment spans a wide continuum of cerebrovascular pathology, ranging from overt large-vessel strokes to more subtle microvascular dysfunction.¹ A central feature of this disease process is impaired cerebral perfusion, wherein ischemic insults and chronic hypoperfusion compromise neuronal integrity and survival. Although traditional paradigms have emphasized macrovascular occlusion and white matter injury, accumulating evidence indicates that more subtle perfusion abnormalities may play an equally critical role in driving cognitive decline.

We seek to highlight an emerging neurological phenomenon that may represent a substantial yet underrecognized contributor to vascular dementia: cerebral slow flow (CSF). While this concept is increasingly recognized through advanced neuroimaging techniques, it remains insufficiently appreciated in clinical practice, despite its potential diagnostic and therapeutic implications in the evaluation and management of vascular cognitive impairment.

CSF is defined as a pathological condition characterized by reduced blood flow velocity within the cerebral microvasculature, constituting a distinct nosological entity that differs from both complete vessel occlusion and conventional chronic hypoperfusion. Critically, CSF is fundamentally distinct from the classic "low blood flow" states that drive vascular dementia through two established mechanisms: supply-side compromise due to macrovascular stenosis, obstruction, or recurrent microembolic events, and demand-side reduction resulting from neuronal loss in neurodegenerative disorders, where metabolic requirements decline. In contrast, CSF reflects a unique pathophysiological condition in where macrovascular anatomy remains intact and cerebral tissue retains normal metabolic demand for oxygen and nutrients, yet a chronic oxygen delivery deficit

arises due to primary microvascular dysfunction. This distinction is mechanistically critical. Whereas traditional reductions in cerebral blood flow (CBF) stem from either insufficient supply at the macrovascular level or diminished metabolic demand due to neuronal loss, CSF originates from a microvascular supply-demand mismatch. In this setting, cerebral metabolic requirements remain preserved; however, impaired flow velocity through patent microvessels produces a state of functional hypoperfusion despite structurally intact vessels. This phenomenon closely parallels the well-characterized coronary slow flow syndrome, in which reduced coronary flow velocity results in myocardial ischemia and anginal symptoms despite angiographically normal coronary arteries. Likewise, primary peripheral slow flow has recently been described as an angiographic entity characterized by delayed contrast progression to the distal peripheral arterial bed, particularly in the lower extremities, in the absence of significant stenotic disease, presenting clinically as claudication and limb pain.² By analogy, CSF may similarly impair cerebral tissue perfusion and neuronal function despite preserved macrovascular circulation and anatomically intact cerebral vessels. In contrast to acute ischemic events caused by abrupt vessel occlusion, or chronic hypoperfusion driven by sustained reductions in cerebral blood volume secondary to supply or demand abnormalities, slow flow represents a distinct and dynamic disturbance of microvascular hemodynamics. This alteration may persist over prolonged periods, establishing a state of chronic cerebral hypoxia without overt infarction and in the context of normal metabolic requirements. The convergence of these features—intact macrovascular patency, preserved neuronal metabolic demand, reduced microvascular flow velocity, and functional tissue hypoxia—supports the conceptualization of CSF as a novel entity within the spectrum of cerebrovascular disorders and justifies its recognition as a distinct pathophysiological mechanism underlying vascular cognitive impairment.

The pathophysiological basis of CSF likely involve mechanisms analogous to those implicated in coronary and peripheral slow



Corresponding author: Uğur Özkan, Department of Cardiology, Trakya University Faculty of Medicine, Edirne, Türkiye

e-mail: drugurozkan@hotmail.com

Received: October 30, 2025 **Accepted:** November 25, 2025 **Available Online Date:** April 1, 2026 • **DOI:** 10.4274/balkanmedj.galenos.2025.2025-10-189

Available at www.balkanmedicaljournal.org

ORCID iDs of the authors: U.Ö. 0000-0002-7552-7654; F.K. 0000-0001-7370-3960; U.V. 0009-0008-1667-4727; K.Y. 0000-0001-5966-2488.

Cite this article as: Özkan U, Kardeş F, Vurucu U, Yalta K. Cerebral Slow Flow: An Emerging Phenomenon in Vascular Dementia Pathogenesis. *Balkan Med J.* 2026;43:222-226

Copyright@Author(s) - Available online at <http://balkanmedicaljournal.org/>

flow, including endothelial dysfunction, reduced nitric oxide (NO) bioavailability, increased oxidative stress, and chronic low-grade inflammation.^{3,4} Collectively, these processes promote elevated microvascular resistance and impaired autoregulatory vasomotion, culminating in sluggish blood flow through structurally normal vessels. In addition, hemorheological abnormalities such as increased blood viscosity, platelet hyperreactivity, and enhanced leukocyte-endothelial interactions, may further aggravate microvascular perfusion deficits (Figure 1). Of particular relevance is the potential contribution of impaired neurovascular coupling, wherein the normal linkage between neuronal activity and regional CBF becomes disrupted. Such uncoupling may lead to insufficient oxygen and nutrient delivery despite preserved vessel patency, thereby promoting chronic cellular stress and progressive cognitive deterioration. Supporting this concept, multiple preclinical models—especially those involving neuroinflammation, sepsis, and transient ischemia-reperfusion injury—have demonstrated microvascular flow disturbances in the absence of large-vessel occlusion, reinforcing the plausibility of a functional, non-obstructive slow-flow state within the cerebral circulation.^{5,6} Collectively, these experimental observations provide an essential framework for understanding the mechanistic basis and clinical consequences of CSF and for directing future translational research efforts.

Historically, the earliest evidence supporting the existence of CSF emerged from investigations of cerebrovascular disease

and vascular dementia using single-photon emission computed tomography and positron emission tomography (PET). These studies consistently demonstrated regional cerebral hypoperfusion in patients with vascular cognitive impairment, even in the absence of structural lesions on conventional imaging.⁷⁻⁹ Despite the limited spatial resolution of these earlier techniques, such findings strongly implicated microvascular dysfunction and contributed to the establishment of CSF as a distinct entity within cerebrovascular pathology.¹⁰ At present, advanced neuroimaging modalities, particularly arterial spin labeling (ASL) magnetic resonance imaging (MRI), have markedly improved the detection of CSF by enabling absolute quantification of CBF (normal values: 50–60 mL/100 g/min in gray matter, 20–25 mL/100 g/min in white matter) and by identifying prolonged arterial transit times (> 1.5–2.0 seconds) indicative of slow flow.^{11,12} Complementary techniques further enhance assessment of microvascular dynamics. These include dynamic susceptibility contrast (DSC) MRI, which provides quantitative measurements of time-to-peak (TTP) delays (delayed by > 2 seconds compared to contralateral regions), mean transit time (MTT) prolongation, and cerebral blood volume, as well as transcranial Doppler ultrasound, which allows real-time evaluation of flow velocities in major cerebral arteries. In this context, a mean flow velocity below 40 cm/s may suggest slow flow, while the pulsatility index and resistance index serve as markers of microvascular resistance. In addition, vasomotor reactivity testing using CO₂ challenge or breath-holding—further elucidate




FIG. 1. Pathophysiological model of cerebral slow flow and clinical spectrum of cerebral perfusion disorders.

CBF, cerebral blood flow; CRP, C-reactive protein; ET-1, endothelin-1; ETA, endothelin A; IL, interleukin; MRI, magnetic resonance imaging; NO, nitric oxide; RBC, red blood cell; TNF-α, tumor necrosis factor-alpha.

microvascular dynamics. High-resolution MRI techniques, such as phase-contrast MRI, permit direct velocity measurements in large cerebral vessels, thereby revealing subtle perfusion abnormalities, including delayed contrast transit times and reduced peak flow velocities.¹⁰ Assessment of the relationship between CBF and metabolic demand can be achieved by combining ASL with functional MRI to evaluate neurovascular coupling efficiency, or through PET imaging with oxygen-15 to determine the oxygen extraction fraction, where elevated values indicate a mismatch between flow and metabolism. Clinically, patients with CSF frequently exhibit executive dysfunction, slowed processing speed, and attention impairment, often preceding overt structural changes such as white matter hyperintensities. This pattern supports the concept that CSF may represent an early and potentially reversible stage along the vascular dementia continuum.¹¹ The integration of detailed cognitive testing with regional perfusion abnormalities provides yields clinically relevant functional correlations. Future investigations should prioritize standardization of these diagnostic tools, establish their specificity and sensitivity, and incorporate comprehensive cognitive assessments alongside blood-based biomarkers, particularly indicators of endothelial dysfunction and inflammation, within longitudinal study designs. Serial imaging performed at 6–12 month intervals will be essential for tracking disease progression and therapeutic response, thereby confirming prognostic value and enabling early intervention.³ At present, no universally accepted quantitative criteria exist for the definition of CSF, in contrast to coronary slow flow, where angiographic metrics such as the corrected TIMI frame count are routinely used to objectively quantify delayed flow. Preliminary ASL-based studies have demonstrated prolonged arterial transit times and reduced peak flow velocities in affected individuals; however, these parameters exhibit considerable variability across populations and imaging protocols.¹¹ The absence of standardized thresholds highlights the urgent need for further investigation to establish normative values and clinically relevant cut-off points. Based upon emerging evidence, we propose preliminary diagnostic criteria for CSF, pending prospective validation: arterial transit time prolongation exceeding 1.5 seconds on ASL; regional CBF reduction below 40 mL/100 g/min in gray matter in the absence of completed infarction, delayed TTP or prolonged MTT on DSC-MRI (> 2 seconds asymmetry), and preserved vessel patency on angiography. The adoption of such thresholds would allow for consistent identification of CSF and facilitate its incorporation into diagnostic algorithms for vascular cognitive impairment. Until these criteria are validated across centers and populations, CSF remains primarily a qualitative imaging observation based on delayed perfusion patterns, underscoring the need for large-scale confirmatory studies.

Vascular risk factors play a central role in the development of CSF and in the modulation of CBF. Established clinical risk factors, including hypertension, diabetes mellitus, dyslipidemia, smoking, chronic kidney disease, and sleep apnea, contribute to CSF through shared pathophysiological mechanisms, such as endothelial dysfunction, oxidative stress, inflammation, and microvascular remodeling.¹³⁻¹⁵ In parallel, lifestyle-related factors, including physical inactivity and poor dietary habits, may exacerbate hemorheological disturbances

by increasing blood viscosity and reducing flow efficiency.¹³ The targeted management of these clinical and lifestyle-related risk factors through interventions—such as antihypertensive therapy, glycemic control, and structured lifestyle modification may therefore mitigate the progression of CSF and its associated cognitive consequences.

The recognition of CSF as a distinct pathophysiological entity carries significant clinical implications for the management of vascular cognitive impairment. Advanced neuroimaging protocols that incorporate perfusion measurements may enable the early identification of patients at risk, prior to the development of irreversible structural brain changes, thereby providing a critical therapeutic window for intervention.¹² Unlike traditional treatment strategies that primarily focus on thrombosis prevention or the management of established vascular lesions, CSF may be particularly amenable to therapies that specifically target microvascular dysfunction. These include pharmacological approaches such as statins, phosphodiesterase inhibitors, and agents that improve endothelial function; strategies to optimize blood rheology through hydration, hematocrit management, and antiplatelet therapy; and interventions aimed at enhancing neurovascular coupling through aerobic exercise and adherence to a Mediterranean dietary pattern.

Although CSF represents a novel diagnostic entity, several therapeutic strategies directed at its underlying mechanisms warrant consideration. On the basis of pathophysiological parallels with coronary slow flow and the mechanisms summarized in Figure 1, potential interventions can be broadly classified into pharmacological and non-pharmacological approaches. Notably, these recommendations remain speculative and require validation through randomized controlled trials specifically designed for CSF patients.

Pharmacological strategies targeting endothelial dysfunction and microvascular regulation may encompass several drug classes. Statins, including atorvastatin at doses of 20–40 mg daily or rosuvastatin at 10–20 mg daily, have been shown to improve endothelial function and attenuate inflammation through pleiotropic effects beyond lipid lowering. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers enhance NO bioavailability and mitigate oxidative stress, thereby addressing key mechanisms implicated in CSF pathogenesis. Cilostazol, administered at 50–100 mg twice daily, a phosphodiesterase-3 inhibitor, has demonstrated cerebrovascular benefits through improvement of endothelial function and inhibition of platelet aggregation, with established efficacy in secondary stroke prevention. Antiplatelet agents, such as aspirin at 75–100 mg daily or clopidogrel at 75 mg daily, may reduce microvascular thrombotic activity that could exacerbate slow flow. Trimetazidine, given at 20 mg three times daily, which has shown benefit in coronary slow flow by enhancing microvascular function via metabolic modulation, represents a potential novel therapeutic option for CSF.

With respect to hemorheological abnormalities, optimization of hematocrit levels, with a target range of 40–45%, through adequate hydration or, in selected cases of polycythemia, therapeutic phlebotomy, may improve flow characteristics. Pentoxifylline,

administered at 400 mg three times daily, enhances red blood cell deformability and lowers blood viscosity, thereby potentially improving microvascular perfusion. Given that CSF reflects a chronic microvascular disorder rather than an acute process, treatment duration should be long-term, with a minimum of 6–12 months and continuous clinical monitoring. The effectiveness of pharmacological therapies requires prospective evaluation using serial perfusion imaging to document improvements in flow velocity and cognitive performance. In the absence of CSF-specific clinical trials, these agents should be prescribed guideline-recommended doses and frequencies used for secondary stroke prevention and high vascular risk populations (e.g., once-daily statin and ACEi/ARB regimens), and maintained on a long-term basis, (at least 6–12 months) with periodic clinical and perfusion imaging follow-up.

Non-pharmacological interventions targeting modifiable risk factors constitute an essential component of CSF management. Regular aerobic exercise, performed at moderate intensity for at least 150 minutes per week, improves cerebrovascular reactivity and strengthens neurovascular coupling. Adherence to a Mediterranean diet pattern reduces systemic inflammation and oxidative stress, directly addressing fundamental mechanisms implicated in CSF pathogenesis. Strict blood pressure control, with a target of less than 130/80 mmHg, limits microvascular remodeling and preserves autoregulation capacity. In patients with diabetes mellitus, glycemic control with a HbA1c target < 7% reduces endothelial dysfunction and the formation of advanced glycation end products. Smoking cessation and weight reduction address multiple vascular risk factors simultaneously. In individuals with coexisting obstructive sleep apnea, continuous positive airway pressure therapy may further improve cerebral hemodynamics and should be systematically incorporated into CSF management strategies.

The combined application of lifestyle-based interventions and pharmacological therapy may yield synergistic benefits, although the optimal combination, and sequencing of these approaches remain to be defined through future clinical trials.

The identification of patients exhibiting slow flow patterns underscores the need for intensified vascular risk factor modification and closer surveillance for cognitive decline.¹³ Moreover, this phenomenon opens new avenues for investigation, particularly with respect to the standardization of imaging protocols for slow flow detection, the establishment of normative reference values across diverse populations, and the development of novel therapeutic strategies targeting microvascular dysfunction. Longitudinal studies evaluating the transition from slow flow to overt vascular cognitive impairment will be critical for defining the natural history of CSF and determining the optimal timing for intervention.

CSF represents a potentially significant and treatable contributor to vascular cognitive impairment that may precede conventional imaging markers of cerebrovascular disease. As understanding of this phenomenon continues to evolve, CSF may emerge as a critical mechanistic link in the pathogenesis of vascular dementia, offering new avenues for early intervention and prevention. We therefore encourage the neurological community to consider CSF in the differential diagnosis of cognitive impairment, particularly

in patients with vascular risk factors but minimal structural abnormalities on conventional imaging. Continued investigation into this entity may ultimately reshape current strategies for the prevention and treatment of vascular cognitive impairment.

This comprehensive diagram illustrates the pathophysiological mechanisms underlying CSF development and its position within the spectrum of cerebral perfusion disorders. The upper portion depicts four key pathophysiological processes surrounding the central cerebrovascular artery cross-section. Endothelial dysfunction in cerebral arteries is characterized by decreased NO production and increased endothelin-1 in endothelial cells, with endothelin A receptor activation and L-arginine pathway disruption leading to reduced vasodilation capacity and impaired autoregulation. The inflammatory response involves leukocytes and inflammatory mediators including interleukin (IL)-1, IL-6, IL-10, tumor necrosis factor-alpha, and C-reactive protein, which contribute to microvascular reactivity and remodeling processes, causing structural and functional changes in endothelial cells and smooth muscle layers. Neurovascular uncoupling, characterized by white matter lipohyalinosis, involves hyaline deposition from astrocytes and endothelial cell alterations, resulting in decreased activity-induced perfusion response. Increased blood viscosity and loss of red blood cell deformability, combined with reduced erythrocyte and platelet deformability, adversely affect microvascular flow. These four mechanisms collectively result in decreased cerebral microvascular flow velocity and functional hypoperfusion. The lower table presents a comparative analysis of cerebral perfusion states, progressing from normal perfusion through CSF, chronic hypoperfusion, to acute ischemia. Each condition is characterized by distinct parameters including blood flow velocity patterns, vessel patency status, clinical presentation, cognitive impact, neuroimaging findings, perfusion characteristics, reversibility potential, and therapeutic approaches. This spectrum demonstrates the progressive nature of cerebrovascular compromise, with CSF representing an intermediate state between normal perfusion and more severe ischemic conditions.

Authorship Contributions: Concept- U.Ö., F.K., K.Y.; Data Collection or Processing- U.V.; Critical Review- U.Ö., K.Y.

Conflict of Interest: No conflict of interest was declared by the authors.

REFERENCES

- Li ML, Zhang F, Huang LT, Wang JH. Development and multi-center validation of a high-performance predictive model for early detection of cognitive impairment in older adults: data-based on communities in Northern China. *Neurol Sci.* 2025;46:5013-5026. [\[CrossRef\]](#)
- Akşit E, Gazi E, Toprak CA, Bozkurt H. Unilateral peripheral slow flow phenomenon without significant stenosis in lower extremity artery: can primary peripheral slow flow be a new phenomenon? *BMJ Case Rep.* 2020;13:e235686. [\[CrossRef\]](#)
- Ma Y, Han Y. Targeting the brain's glymphatic pathway: a novel therapeutic approach for cerebral small vessel disease. *Neural Regen Res.* 2026;21:433-442. [\[CrossRef\]](#)
- Akşit E, Gazi E, Kırılmaz B, Aydın F. A new angiographic finding: primary peripheral slow flow. *Balkan Med J.* 2021;38:139-140. [\[CrossRef\]](#)
- Takata F, Nakagawa S, Matsumoto J, Dohgu S. Blood-brain barrier dysfunction amplifies the development of neuroinflammation: understanding of cellular events in brain microvascular endothelial cells for prevention and treatment of BBB dysfunction. *Front Cell Neurosci.* 2021;15:661838. [\[CrossRef\]](#)

6. Fruekilde SK, Bailey CJ, Lambertsen KL, et al. Disturbed microcirculation and hyperaemic response in a murine model of systemic inflammation. *J Cereb Blood Flow Metab.* 2022;42:2303-2317. [\[CrossRef\]](#)
7. Jagust WJ, Eberling JL, Reed BR, Mathis CA, Budinger TF. Clinical studies of cerebral blood flow in Alzheimer's disease. *Ann N Y Acad Sci.* 1997;826:254-262. [\[CrossRef\]](#)
8. Weijs RWJ, Shkredova DA, Brekelmans ACM, Thijssen DHJ, Claassen JAHR. Longitudinal changes in cerebral blood flow and their relation with cognitive decline in patients with dementia: current knowledge and future directions. *Alzheimers Dement.* 2023;19:532-548. [\[CrossRef\]](#)
9. Tanaka M, Kondo S, Okamoto K, Hirai S. Vascular dementia from a viewpoint of cerebral blood flow and oxygen metabolism. *Psychogeriatrics.* 2003;3:3-10. [\[CrossRef\]](#)
10. Pan Y, Wan W, Xiang M, Guan Y. Transcranial Doppler ultrasonography as a diagnostic tool for cerebrovascular disorders. *Front Hum Neurosci.* 2022;16:841809. [\[CrossRef\]](#)
11. van Dinther M, Hooghiemstra AM, Bron EE, et al; Heart-Brain Connection consortium. Lower cerebral blood flow predicts cognitive decline in patients with vascular cognitive impairment. *Alzheimers Dement.* 2024;20:136-144. [\[CrossRef\]](#)
12. Hanapi NA, Halim SA, Razak AA, Sapiai NA. Roles of arterial spin labelling in cognitive impairment: case series. *Radiol Case Rep.* 2024;19:4736-4740. [\[CrossRef\]](#)
13. Kimura N, Sasaki Y, Masuda T, et al. Lifestyle factors that affect cognitive function-a longitudinal objective analysis. *Front Public Health.* 2023;11:1215419. [\[CrossRef\]](#)
14. Baggeroer CE, Cambronerero FE, Savan NA, Jefferson AL, Santisteban MM. Basic mechanisms of brain injury and cognitive decline in hypertension. *Hypertension.* 2024;81:34-44. [\[CrossRef\]](#)
15. Mao Z, Zheng P, Zhu X, et al. Obstructive sleep apnea hypopnea syndrome and vascular lesions: an update on what we currently know. *Sleep Med.* 2024;119:296-311. [\[CrossRef\]](#)